Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses trials and progress in myeloproliferative neoplasms (MPNs) at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin discusses the role of ruxolitinib in myelofibrosis, the failure many second-line agents and the importance of having another agent. She also mentions how her group has reported on the polycythaemia vera (PV) and essential thrombocythaemia (ET) MAJIC trial (ISRCTN61925716).